EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subcellular localization of PD‐L1 and cell‐cycle‐dependent expression of nuclear PD‐L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy

Daniela Schulz, Laura Feulner, Dominique Santos Rubenich, Sina Heimer, Sophia Rohrmüller, Yvonne Reinders, Marcelo Falchetti, Martin Wetzel, Elizandra Braganhol, Edroaldo Lummertz da Rocha, Nicole Schäfer, Sabine Stöckl und 7 weitere

Molecular Oncology · 2024-02 · 18 (2) · 431-452

DOI: 10.1002/1878-0261.13567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, online erschienen am 26.12.2023. Verfasst von Daniela Schulz und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Germany. Hauptthemen laut MEDLINE: B7-H1 Antigen, Head and Neck Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The programmed cell death 1 ligand 1 (PD‐L1)/programmed cell death protein 1 (PD‐1) axis is primarily associated with immunosuppression in cytotoxic T lymphocytes (CTLs). However, mounting evidence is supporting the thesis that PD‐L1 not only functions as a ligand but mediates additional cellular functions in tumor cells. Moreover, it has been demonstrated that PD‐L1 is not exclusively localized at the cellular membrane. Subcellular fractionation revealed the presence of PD‐L1 in various cellular compartments of six well‐characterized head and neck cancer (HNC) cell lines, including the nucleus. Via Western blotting, we detected PD‐L1 in its well‐known glycosylated/deglycosylated state at 40–55 kDa. In addition, we detected previously unknown PD‐L1 variants with a molecular weight at approximately 70 and > 150 kDa exclusively in nuclear protein fractions. These in vitro findings were confirmed with primary tumor samples from head and neck squamous cell carcinoma (HNSCC) patients. Furthermore, we demonstrated that nuclear PD‐L1 variant expression is cell‐cycle‐dependent. Immunofluorescence staining of PD‐L1 in different cell cycle phases of synchronized HNC cells supported these observations. Mechanisms of nuclear PD‐L1 trafficking remain less understood; however, proximity ligation assays showed a cell‐cycle‐dependent interaction of the cytoskeletal protein vimentin with PD‐L1, whereas vimentin could serve as a potential shuttle for nuclear PD‐L1 transportation. Mass spectrometry after PD‐L1 co‐immunoprecipitation, followed by gene ontology analysis, indicated interaction of nuclear PD‐L1 with proteins involved in DNA remodeling and messenger RNA (mRNA) splicing. Our results in HNC cells suggest a highly complex regulation of PD‐L1 and multiple tumor cell‐intrinsic functions, independent of immune regulation. These observations bear significant implications for the therapeutic efficacy of immune checkpoint inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenHead and Neck NeoplasmsHumansCell CycleSquamous Cell Carcinoma of Head and NeckVimentin

Stichwörter der Autor:innen

DNA remodelingHNSCCnPD-L1nuclear traffickingsubcellular protein fractionationvimentin immunotherapy

Substanzen

B7-H1 AntigenVimentinCD274 protein, human

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Germany.
  • Department of Oral and Maxillofacial Surgery, Experimental Oral and Maxillofacial Surgery, Center for Medical Biotechnology, University Hospital Regensburg, Germany.
  • Postgraduation program in Biosciences, Federal University of Health Sciences from Porto Alegre, Brazil.
  • Leibniz-Institute for Analytical Sciences, ISAS e.V., Dortmund, Germany.
  • Department of Microbiology, Immunology and Parasitology, Federal University of Santa Catarina, Florianópolis, Brazil.
  • Department of Basic Health Sciences, Federal University of Health Sciences from Porto Alegre, Brazil.

ORCID-Profile: Richard J Bauer

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Schulz, D., Feulner, L., Santos Rubenich, D., Heimer, S., Rohrmüller, S., Reinders, Y., Falchetti, M., Wetzel, M., Braganhol, E., Lummertz da Rocha, E., Schäfer, N., Stöckl, S., Brockhoff, G., Wege, A. K., Fritsch, J., Pohl, F., Reichert, T. E., Ettl, T., & Bauer, R. J. (2024). Subcellular localization of PD‐L1 and cell‐cycle‐dependent expression of nuclear PD‐L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy. Molecular Oncology, 18(2), 431-452. https://doi.org/10.1002/1878-0261.13567

Vancouver

Schulz D, Feulner L, Santos Rubenich D, Heimer S, Rohrmüller S, Reinders Y, et al. Subcellular localization of PD‐L1 and cell‐cycle‐dependent expression of nuclear PD‐L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy. Molecular Oncology. 2024;18(2):431-452. doi:10.1002/1878-0261.13567

BibTeX
@article{Schulz2024,
  author = {Schulz, Daniela and Feulner, Laura and Santos Rubenich, Dominique and Heimer, Sina and Rohrmüller, Sophia and Reinders, Yvonne and Falchetti, Marcelo and Wetzel, Martin and Braganhol, Elizandra and Lummertz da Rocha, Edroaldo and Schäfer, Nicole and Stöckl, Sabine and Brockhoff, Gero and Wege, Anja K and Fritsch, Jürgen and Pohl, Fabian and Reichert, Torsten E and Ettl, Tobias and Bauer, Richard J},
  title = {Subcellular localization of PD‐L1 and cell‐cycle‐dependent expression of nuclear PD‐L1 variants: implications for head and neck cancer cell functions and therapeutic efficacy},
  journal = {Molecular Oncology},
  year = {2024},
  volume = {18},
  number = {2},
  pages = {431--452},
  doi = {10.1002/1878-0261.13567}
}
Kostenlos starten →